Yusimry™ (adalimumab biosimilar)
Chronic Inflammatory Diseases (e.g., Rheumatoid Arthritis, Psoriasis, Crohn's Disease)
ApprovedMarketed in EU
Key Facts
Indication
Chronic Inflammatory Diseases (e.g., Rheumatoid Arthritis, Psoriasis, Crohn's Disease)
Phase
Approved
Status
Marketed in EU
Company
About Dermapharm
Dermapharm Holding SE is a Germany-based pharmaceutical group with a core focus on dermatology and other therapeutic areas such as cardiovascular, pain, and anti-infectives. The company operates through two main segments: 'Branded Pharmaceuticals and Other Healthcare Products' and 'Parallel Import Business'. Its strategy is built on a 'buy-and-build' approach, acquiring and integrating established pharmaceutical brands and companies to drive growth. Dermapharm is listed on the Frankfurt Stock Exchange and has achieved significant scale with a market valuation in the billions.
View full company profile